％0期刊论文％A Jogdand，Prajakta％A Siddhuraj，Premkumar％A森，美智子％A三电，卡罗琳％A乔森，吉米％A墙壁，安德鲁F.％A Kearley，詹妮弗％A谦卑，艾莉森A.％AKolbeck，罗兰％A Bjermer，雷夫％A纽伯尔德，保罗％AErjefält纳斯S.％T嗜酸性粒细胞，嗜碱性粒细胞，和2型免疫微环境在COPD不受影响的肺组织％d 2020％R 10.1183 / 13993003.00110-2019％Ĵ欧洲呼吸杂志％P 1900110％X尽管升高的血或痰嗜酸粒细胞存在于许多患者的慢性阻塞性肺疾病（COPD），仍然存在不确定性关于肺浸润嗜酸性粒细胞的解剖分布图案。嗜碱性粒细胞仍然在COPD几乎未开发的。本研究映射组织浸润嗜酸性粒细胞，嗜碱性粒细胞，嗜酸性粒细胞和促进免疫机制在COPD影响lungs.Surgical肺组织和活检从主要解剖隔间从COPD患者获得具有强度等级GOLD I-IV;从不吸烟者/吸烟者作为对照。自动免疫组织化学和原位杂交鉴定的免疫细胞，2型免疫标记GATA3，和eotaxins（CCL11，CCL24）.Eosinophils和嗜碱性粒细胞存在于慢性阻塞性肺病，肺受影响的所有解剖室和在极重度COPD显著增加。的嗜酸粒细胞增多是显着片状，和焦富嗜酸性粒细胞微环境空间上与GATA3 +细胞连接，包括Th2淋巴细胞和2型先天性淋巴样细胞。类似的本地化和IL-33 / ST2依赖性嗜酸性粒细胞表现在流感感染的小鼠。小鼠和患者显示的空间上的限制与CCL11 +成纤维细胞和CCL24 + macrophages.In除了eotaxin的签名来识别组织嗜碱性作为晚期COPD一个新颖的特征，空间受限丰富嗜酸性粒细胞型2的微环境的识别代表了免疫病理学的新颖类型的异质性的 of COPD that will likely have implications for personalised treatment.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Jogdand has nothing to disclose.Conflict of interest: Dr. Siddhuraj has nothing to disclose.Conflict of interest: Dr. Mori has nothing to disclose.Conflict of interest: Dr. Sanden has nothing to disclose.Conflict of interest: Dr. Jönsson has nothing to disclose.Conflict of interest: Dr. Walls has nothing to disclose.Conflict of interest: Dr. Kearley reports other from MedImmune LLC, other from AstraZeneca, outside the submitted work.Conflict of interest: Dr. Humbles reports other from MedImmune LLC, other from AstraZeneca, outside the submitted work.Conflict of interest: Dr. Kolbeck reports other from MedImmune LLC, other from AstraZeneca, outside the submitted work.Conflict of interest: Dr. Bjermer has nothing to disclose.Conflict of interest: Dr. Newbold reports other from MedImmune LLC, other from AstraZeneca, outside the submitted work.Conflict of interest: Dr. Erjefält reports: JE is founder (and stock owner) of Medetect AB who recieved funding from AstraZeneca for conducting parts of the present study. %U //www.qdcxjkg.com/content/erj/early/2020/02/06/13993003.00110-2019.full.pdf